Adjuvanted Influenza Vaccines Elicits Higher Antibody Responses against the A(H3N2) Subtype than Non-Adjuvanted Vaccines

Laura Sánchez De Prada,José María Eiros Bouza,Javier Castrodeza Sanz,Iván Sanz Muñoz,Raúl Ortiz De Lejarazu Leonardo

doi:10.3390/vaccines8040704

Laura Sánchez De Prada, José María Eiros Bouza + Show 3 more

Open Access

https://doi.org/10.3390/vaccines8040704

Copy DOI

Abstract

Background: vaccination is the best approach to prevent influenza infections so far. Serological studies on the effect of different vaccine types are important to address vaccination campaigns and protect our population. In our study, we compared the serological response against influenza A subtypes using the non-adjuvanted influenza vaccine (NAIV) in adults and the elderly and the adjuvanted influenza vaccine (AIV) in the elderly. Methods: We performed a retrospective analysis by hemagglutination inhibition assay (HI) of serum samples right before and 28 days after seasonal influenza vaccination during the 1996–2017 seasons. Conclusions: The AIV presents better performance against the A(H3N2) subtype in the elderly whereas the NAIV induces a better response against A(H1N1)pdm09 in the same group.

Highlights

Influenza viruses circulate widely, causing seasonal epidemics in both hemispheres during the winter months
The median age was significantly higher in those ≥65 years who received an adjuvanted influenza vaccine (AIV) than those who received an non-adjuvanted influenza vaccine (NAIV) (Mann–Whitney, p < 0.05); the median age was significantly higher in both elderly groups than in adults (Mann–Whitney, p < 0.05)
Our data showed that seroprotection prior to influenza vacCI nation, which was analyzed by calculation of geometric mean titers (GMTs) and seroprotection rate (SPR), was similar against the A(H3N2) subtype in both elderly groups calculation of GMTs and SPR, was similar against the A(H3N2) subtype in both elderly groups and and adults

Summary

Introduction

Influenza viruses circulate widely, causing seasonal epidemics in both hemispheres during the winter months. This disease causes 2–5 million hospitalizations and over 650,000 deaths worldwide each year [1]. The presentation of influenza disease ranges from an asymptomatic infection to a fulminant illness, depending on the characteristics of both the host and virus. We compared the serological response against influenza A subtypes using the non-adjuvanted influenza vaccine (NAIV) in adults and the elderly and the adjuvanted influenza vaccine (AIV) in the elderly. Conclusions: The AIV presents better performance against the A(H3N2) subtype in the elderly whereas the NAIV induces a better response against A(H1N1)pdm in the same group

Objectives

Methods

Results

Discussion

Conclusion